SG11201405214YA - Method for selecting or identifying a subject for v1b antagonist therapy - Google Patents
Method for selecting or identifying a subject for v1b antagonist therapyInfo
- Publication number
- SG11201405214YA SG11201405214YA SG11201405214YA SG11201405214YA SG11201405214YA SG 11201405214Y A SG11201405214Y A SG 11201405214YA SG 11201405214Y A SG11201405214Y A SG 11201405214YA SG 11201405214Y A SG11201405214Y A SG 11201405214YA SG 11201405214Y A SG11201405214Y A SG 11201405214YA
- Authority
- SG
- Singapore
- Prior art keywords
- identifying
- selecting
- subject
- antagonist therapy
- antagonist
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/30—Psychoses; Psychiatry
- G01N2800/304—Mood disorders, e.g. bipolar, depression
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261610101P | 2012-03-13 | 2012-03-13 | |
| PCT/EP2013/055147 WO2013135769A1 (en) | 2012-03-13 | 2013-03-13 | Method for selecting or identifying a subject for v1b antagonist therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201405214YA true SG11201405214YA (en) | 2014-10-30 |
Family
ID=47846064
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201405214YA SG11201405214YA (en) | 2012-03-13 | 2013-03-13 | Method for selecting or identifying a subject for v1b antagonist therapy |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20130245038A1 (en) |
| EP (1) | EP2825891A1 (en) |
| JP (1) | JP2015512892A (en) |
| KR (1) | KR20140147837A (en) |
| CN (1) | CN104303060A (en) |
| AU (1) | AU2013231230A1 (en) |
| BR (1) | BR112014018717A8 (en) |
| CA (1) | CA2866220A1 (en) |
| HK (1) | HK1205789A1 (en) |
| MX (1) | MX2014011045A (en) |
| RU (1) | RU2014141059A (en) |
| SG (1) | SG11201405214YA (en) |
| WO (1) | WO2013135769A1 (en) |
| ZA (1) | ZA201406518B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140046407A1 (en) * | 2001-08-31 | 2014-02-13 | Bio Control Medical (B.C.M.) Ltd. | Nerve stimulation techniques |
| CN109030828A (en) * | 2018-06-21 | 2018-12-18 | 大连民族大学 | A kind of ELISA detection kit and detection method detecting histidine phosphorylated protein |
| CN108845145A (en) * | 2018-06-21 | 2018-11-20 | 大连民族大学 | A method of detection histidine kinase activity |
| CN114624344A (en) * | 2020-12-10 | 2022-06-14 | 中国科学院大连化学物理研究所 | Steroid hormone combined biomarker and application thereof |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1362776A (en) * | 1970-07-17 | 1974-08-07 | Wellcome Found | Immunological reagent |
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| GB8311018D0 (en) | 1983-04-22 | 1983-05-25 | Amersham Int Plc | Detecting mutations in dna |
| ES2063735T3 (en) | 1986-10-22 | 1995-01-16 | Abbott Lab | CHEMI-LUMINISCENT ACRIDINY SALTS. |
| US5241070A (en) | 1988-09-26 | 1993-08-31 | Ciba Corning Diagnostics Corp. | Nucleophilic polysubstituted aryl acridinium esters and uses thereof |
| US5028535A (en) | 1989-01-10 | 1991-07-02 | Biosite Diagnostics, Inc. | Threshold ligand-receptor assay |
| US5939272A (en) | 1989-01-10 | 1999-08-17 | Biosite Diagnostics Incorporated | Non-competitive threshold ligand-receptor assays |
| FR2650840B1 (en) | 1989-08-11 | 1991-11-29 | Bertin & Cie | RAPID DETECTION AND / OR IDENTIFICATION OF A SINGLE BASED ON A NUCLEIC ACID SEQUENCE, AND ITS APPLICATIONS |
| US5922615A (en) | 1990-03-12 | 1999-07-13 | Biosite Diagnostics Incorporated | Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network |
| WO1992005282A1 (en) | 1990-09-14 | 1992-04-02 | Biosite Diagnostics, Inc. | Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays |
| AU1911592A (en) | 1991-04-10 | 1992-11-17 | Biosite Diagnostics Incorporated | Novel conjugates and assays for simultaneous detection of multiple ligands |
| ATE177841T1 (en) | 1991-04-10 | 1999-04-15 | Biosite Diagnostics Inc | CROSSTALK OR CROSSTALK INHIBITORS AND THEIR USE |
| CA2131727A1 (en) | 1992-03-30 | 1993-10-14 | Diana E. Clarisse | Reagents and methods for the detection and quantification of thyroxine in fluid samples |
| US5352803A (en) | 1992-03-30 | 1994-10-04 | Abbott Laboratories | 5(6)-methyl substituted fluorescein derivatives |
| US6143576A (en) | 1992-05-21 | 2000-11-07 | Biosite Diagnostics, Inc. | Non-porous diagnostic devices for the controlled movement of reagents |
| US6019944A (en) | 1992-05-21 | 2000-02-01 | Biosite Diagnostics, Inc. | Diagnostic devices and apparatus for the controlled movement of reagents without membranes |
| US5824799A (en) | 1993-09-24 | 1998-10-20 | Biosite Diagnostics Incorporated | Hybrid phthalocyanine derivatives and their uses |
| US6113855A (en) | 1996-11-15 | 2000-09-05 | Biosite Diagnostics, Inc. | Devices comprising multiple capillarity inducing surfaces |
| US5947124A (en) | 1997-03-11 | 1999-09-07 | Biosite Diagnostics Incorporated | Diagnostic for determining the time of a heart attack |
| MXPA03000506A (en) | 2000-07-18 | 2004-09-10 | Correlogic Systems Inc | A process for discriminating between biological states based on hidden patterns from biological data. |
| US6890763B2 (en) | 2001-04-30 | 2005-05-10 | Syn X Pharma, Inc. | Biopolymer marker indicative of disease state having a molecular weight of 1350 daltons |
| WO2003095978A2 (en) | 2002-05-09 | 2003-11-20 | Surromed, Inc. | Methods for time-alignment of liquid chromatography-mass spectrometry data |
| BR0309976A (en) * | 2002-05-13 | 2005-03-01 | Becton Dickinson Co | Protease Inhibitor Sample Collection System |
| WO2008137270A1 (en) * | 2007-05-04 | 2008-11-13 | H. Lundbeck A/S | Methods of diagnosing and monitoring of npy y5 based disorders |
| JP5658571B2 (en) * | 2008-03-12 | 2015-01-28 | リッジ ダイアグノスティックス，インコーポレイテッド | Inflammatory biomarkers for monitoring depression disorders |
| WO2009130232A1 (en) * | 2008-04-24 | 2009-10-29 | Glaxo Group Limited | Pyrazolo [1, 5 -a] pyrazine derivatives as antagonists of v1b receptors |
| DK2452194T3 (en) * | 2009-07-10 | 2015-11-30 | Transgene Sa | Biomarker PATIENT SELECTION AND RELATED PRACTICES |
-
2013
- 2013-03-13 WO PCT/EP2013/055147 patent/WO2013135769A1/en active Application Filing
- 2013-03-13 EP EP13708854.8A patent/EP2825891A1/en not_active Withdrawn
- 2013-03-13 MX MX2014011045A patent/MX2014011045A/en unknown
- 2013-03-13 AU AU2013231230A patent/AU2013231230A1/en not_active Abandoned
- 2013-03-13 CN CN201380014125.3A patent/CN104303060A/en active Pending
- 2013-03-13 JP JP2014561437A patent/JP2015512892A/en not_active Withdrawn
- 2013-03-13 CA CA2866220A patent/CA2866220A1/en not_active Abandoned
- 2013-03-13 RU RU2014141059A patent/RU2014141059A/en not_active Application Discontinuation
- 2013-03-13 BR BR112014018717A patent/BR112014018717A8/en not_active IP Right Cessation
- 2013-03-13 SG SG11201405214YA patent/SG11201405214YA/en unknown
- 2013-03-13 KR KR1020147028639A patent/KR20140147837A/en not_active Application Discontinuation
- 2013-03-13 US US13/798,360 patent/US20130245038A1/en not_active Abandoned
-
2014
- 2014-09-04 ZA ZA2014/06518A patent/ZA201406518B/en unknown
-
2015
- 2015-07-02 HK HK15106312.1A patent/HK1205789A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013231230A8 (en) | 2014-08-14 |
| ZA201406518B (en) | 2018-05-30 |
| CN104303060A (en) | 2015-01-21 |
| CA2866220A1 (en) | 2013-09-19 |
| MX2014011045A (en) | 2015-04-10 |
| HK1205789A1 (en) | 2015-12-24 |
| US20130245038A1 (en) | 2013-09-19 |
| BR112014018717A2 (en) | 2017-06-20 |
| BR112014018717A8 (en) | 2017-07-11 |
| JP2015512892A (en) | 2015-04-30 |
| AU2013231230A1 (en) | 2014-08-07 |
| WO2013135769A1 (en) | 2013-09-19 |
| EP2825891A1 (en) | 2015-01-21 |
| RU2014141059A (en) | 2016-04-27 |
| KR20140147837A (en) | 2014-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL234875B (en) | Method for detecting copy number variation | |
| EP2847353A4 (en) | Methods for determining a nucleotide sequence | |
| ZA201501833B (en) | Method for obtaining 1-kestone | |
| EP2897709A4 (en) | A method for separating cells-bead complexes | |
| HK1208534A1 (en) | A method for authenticating a timepiece | |
| EP2817735A4 (en) | A system and a method for determining context | |
| PL2722378T3 (en) | Method for fracturing or fraccing a well | |
| EP2689889A4 (en) | Machine tool system | |
| EP2876447A4 (en) | Method for detecting cancer | |
| HUE043162T2 (en) | Method for detecting cancer | |
| HK1208271A1 (en) | Method for authenticating a timepiece | |
| HK1208731A1 (en) | Method for the detection of a multispecific binder | |
| EP2800924A4 (en) | System and method for relubricating a machine element | |
| HK1205798A1 (en) | Method for authenticating a timepiece | |
| HK1205789A1 (en) | Method for selecting or identifying a subject for v1b antagonist therapy v1b | |
| HRP20190390T1 (en) | A method for preparing oxycodone | |
| HK1210480A1 (en) | A method for polishing albumin | |
| EP2931743A4 (en) | Methods for assessing immunogenicity | |
| HK1168501A2 (en) | A positioning method | |
| EP2862034A4 (en) | Method for determining a machine condition | |
| GB201211637D0 (en) | A barrier apparatus | |
| IL233868B (en) | Method for detecting polymavirus reactivation | |
| HK1206815A1 (en) | Selection method for therapeutic agents | |
| GB2500319B (en) | Method of testing the integrity of a barrier | |
| EP2850814A4 (en) | An apparatus or a method |